WO2023012690 - NOVEL OMEGA 3 CARRIER PREPARATIONS FOR INHALATION DRUG DELIVERY FOR TREATING LUNG INFLAMMATION
National phase entry:
Publication Number
WO/2023/012690
Publication Date
09.02.2023
International Application No.
PCT/IB2022/057208
International Filing Date
03.08.2022
Title **
[English]
NOVEL OMEGA 3 CARRIER PREPARATIONS FOR INHALATION DRUG DELIVERY FOR TREATING LUNG INFLAMMATION
[French]
NOUVELLES PRÉPARATIONS DE SUPPORT OMÉGA 3 DESTINÉES À L'ADMINISTRATION DE MÉDICAMENT PAR INHALATION POUR LE TRAITEMENT D'UNE INFLAMMATION PULMONAIRE
Applicants **
LEIUTIS PHARMACEUTICALS LLP
Inventors
KOCHERLAKOTA, Chandrashekhar
BRENNA, James Thomas
KOTHAPALLI, Sesha Durga Kumar
BANDA, Nagaraju
NARALA, Arjun
AKULA, Srinath
Priority Data
202141035170
04.08.2021
IN
202141053853
23.11.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP India
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2758 | |
| EPO | Filing, Examination, Granting | 18295 | |
| Japan | Filing, Examination, Granting | 2493 | |
| South Korea | Filing, Examination, Granting | 2894 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
32,980
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Inflammatory disorders of the lung are induced by COVID-19 disease, asthma, and numerous other disorders. Omega- 3 fatty acids (O3FA), particularly docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) or eicosapentaenoic acid (EPA), have known anti-inflammatory and pro-resolving properties. Reduction of lung pathology and inflammation will be accomplished by a mixture incorporating O3FA that is suitable for nebulization using formulas and nebulization apparatus known in the art. The O3FA may be delivered in the form of ethyl esters (EE) or free fatty acid (FEA) oils or non- phosphate- containing glycerolipids or as phospholipids (PL) or as any other form known in the art. The mixture can also be delivered in any of the other forms of inhaled droplet or solids for inhalation known in the art. The patient will inhale for a therapeutically effective period of time to reduce inflammation and improve breathing.[French]
Les troubles inflammatoires du poumon sont induits par la maladie COVID-19, l'asthme et de nombreux autres troubles. Les acides gras oméga-3 (O3FA), en particulier l'acide docosahexaénoïque (DHA), l'acide docosapentaénoïque (DPA) ou l'acide eicosapentaénoïque (EPA), ont des propriétés anti-inflammatoires et pro-résolution connues. La réduction de la pathologie pulmonaire et de l'inflammation est effectuée par un mélange incorporant de l'O3FA qui est approprié pour la nébulisation à l'aide de formules et d'un appareil de nébulisation connus dans l'état de la technique. L'O3FA peut être administré sous la forme d'esters éthyliques (EE) ou d'huiles d'acides gras libres (FEA) ou de glycérolipides ne contenant pas de phosphate ou en tant que phospholipides (PL) ou sous toute autre forme connue dans l'état de la technique. Le mélange peut également être administré sous l'une quelconque des autres formes de gouttelettes inhalées ou de solides pour inhalation connues dans l'état de la technique. Le patient inhale pendant une durée thérapeutiquement efficace afin de réduire l'inflammation et d'améliorer la respiration.